Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents

Japanese Journal of Medical Mycology

Volumn 45, Issue 2, 2004, Pages 101-104

  Zeng, Jingsi ^a,b   Kamei, Katsuhiko ^a   Zheng, Yuecheng ^b   Nishimura, Kazuko ^a  

^a CHIBA UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antifungal susceptibility; Micafungin; P. boydii; S. apiospermum; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; MICONAZOLE; NEW DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; FUNGUS ISOLATION; HYALOHYPHOMYCOSIS; M38 P MICRODILUTION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PETRIELLIDIUM BOYDII; SCEDOSPORIUM APIOSPERMUM;

CANDIDA; CANDIDA ALBICANS; FUNGI; PSEUDALLESCHERIA; PSEUDALLESCHERIA BOYDII; SCEDOSPORIUM;

EID: 2442681469     PISSN: 09164804     EISSN: None     Source Type: Journal    
DOI: 10.3314/jjmm.45.101     Document Type: Article

References (12)

1. Kwon-Chung KJ, Bennett JE: Pseudallescheriasis and Scedosporium infection. In Medical Mycology, p.678-694, Lea & Febiger, Philadelphia, 1992.
2. Espinel-Ingroff A: In vitro activity of the new triazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36: 198-202, 1998.
3. Macor F, Pfaller MA, Messer SA, Jones RN: Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 36: 433-436, 1998.
4. Johnson EM, Szekely A, Warnock DW: In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 42: 741-745, 1998.
5. Meletiadis J, Meis JFGM, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE, the EUROFUNG Network: In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 46: 62-68, 2002.
6. Carrillo AJ, Guarro J: In vitro activities of four novel triazoles against Scedosporium spp.. Antimicrob Agents Chemother 45: 2151-2153, 2001.
7. Nakai T, Uno J, Otomo K, Ikeda F, Tawara S, Goto T, Nishimura K, Miyaji M: In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 48: 78-81, 2002.
8. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H: In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiotics 53: 1175-1181, 2000.
9. National Committee for Clinical Laboratory. Reference method for dilution antifungal susceptibility testing of conidium-forming filamentous fungi: proposed standard. NCCLS document M38-P, National Committee for Clinical Laboratory Standards, Wayne, Philadelphia, 1998.
10. Nielson HS Jr: Effects of amphotericin B in vitro on perfect and imperfect strains of Allescheria boydii. Appl Microbiol 15: 86-91, 1967.
11. Cuenca-Estrella M, Ruiz-Diez B, Martinez-Suarez JV, Monzon A, Rodriguez-Tudela JL: Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 43: 149-151, 1999.
12. Del Poeta M, Schell WA, Perfect JR: In vitro antifungal activity of pneumocandin L743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 41: 1835-1836, 1997.